1. Smith I, Procter M, Gelber R, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007;369:29–36. [PubMed] 2. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72. [PubMed] 3. Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48. [PubMed]
4. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 06 study[abstract 1]. Breast Cancer Rest Treat; Data presented at the San Antonio Breast Cancer Symposium.2005.
5. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer: combined analysis of NSABP B-31 and NCCTG N9831. N Engl J Med. 2005;353:1673–84. [PubMed] 6. Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008;61:553–60. [PubMed] 7. Haffty BG, Yang Q, Reiss M. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–7. [PubMed] 8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–502. [PubMed] 9. Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32. [PubMed] 10. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109:1721–8. [PubMed] 11. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet. 2007;8:235–44. [PubMed] 12. Stockmans G, Deraedt K, Wildiers H, et al. Triple-negative breast cancer. Curr Opin Oncol. 2008;20:614–20. [PubMed] 13. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52. [PubMed] 14. Foulkes W, Smith I, Reis-Filho J. Triple-Negative Breast Cancer. N Engl J Med. 2010;363:1938–48. [PubMed] 15. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–81. [PubMed] 16. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74. [PubMed] 17. Birnbaum D, Bertucci F, Ginestier C, et al. Basal and luminal breast cancers: basic or luminous? Int J Oncol. 2004;25:249–58. [PubMed] 18. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34. [PMC free article] [PubMed]
19. Fulford LG, Easton DF, Sofronis A, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinomas of the breast. Pathol Int. 2004;54:A2–3.
20. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18:1321–8. [PubMed] 21. Matos I, Dufloth R, Alvarenga M, et al. p53, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–94. [PubMed] 22. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–8. [PubMed] 23. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65. [PMC free article] [PubMed] 24. Jacquemeier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260–8. [PubMed] 25. Dent R, Trudeau M, Pritchard K, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34. [PubMed] 26. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236–40. [PubMed]
27. Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC) J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):508.
28. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71. [PubMed] 29. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–80. [PubMed] 30. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–5. [PubMed] 31. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23. [PubMed] 32. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9. [PubMed] 33. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;14:2126–32. [PubMed] 34. Adelaide J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007;67:11565–75. [PubMed] 35. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;9819:10869–74. [PubMed] 36. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncologica. 2000;39:327–33. [PubMed] 37. Reis-Filho JS, Tutt AJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108–18. [PubMed] 38. Young S, Pilarski R, Donenburg T, et al. The prevalence of BRCA mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86. [PMC free article] [PubMed] 39. Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–20. [PubMed] 40. Herschkowitz J, Simin K, Weigman V, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76. [PMC free article] [PubMed] 41. Prat A, Parker J, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. [PMC free article] [PubMed] 42. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106:13820–925. [PubMed] 43. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16:61–70. [PubMed] 44. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. 2011;5:5–23. [PubMed] 45. Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Persepct Biol. 2011;3 [PMC free article] [PubMed] 46. Morris G, Naidu S, Topham K, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and end results database. Cancer. 2007;110:876–84. [PubMed] 47. Freedman G, Anderson P, Li T, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115:946–51. [PMC free article] [PubMed] 48. Millikan R, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123–39. [PMC free article] [PubMed] 49. Lund M, Butler E, Hair B, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010;116:2549–59. [PubMed] 50. Lund M, Butler E, Bumpers H, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008;113:608–15. [PubMed] 51. Tischkowitz M, Brunet J, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134. [PMC free article] [PubMed] 52. Phipps A, Malone K, Porter P, et al. Reproductive and hormonal risk factors for postmenopausal luminal, Her-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113:1521–6. [PMC free article] [PubMed] 53. Yang X, Sherman M, Rimm D, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16:439–43. [PubMed] 54. Trivers K, Lund M, Porter P, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–82. [PubMed] 55. Yang XR, Pfeiffer RM, Garcia-Cloases M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res. 2007;67:10608–17. [PubMed] 56. Kwan M, Kushi L, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31. [PMC free article] [PubMed] 57. Slattery M, Sweeney C, Edwards S, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Rest Treat. 2007;102:85–101. [PubMed] 58. Maiti B, Kundranda MN, Jin T, et al. The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol. 2009;27:479–83. [PubMed] 59. Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191:657–64. [PubMed] 60. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typically medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24. [PMC free article] [PubMed] 61. Rakha E, Ellis I. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41:40–7. [PubMed] 62. Bhargava R, Geral WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027–33. [PubMed] 63. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20. [PubMed] 64. Fulford G, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4. [PMC free article] [PubMed] 65. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–6. [PubMed] 66. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76. [PubMed] 67. Rakha E, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and non-basal subtypes. Clin Cancer Res. 2009;15:2302–10. [PubMed] 68. Liu H, Fan Q, Zhang Z, Xiao L, Huiping Y, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167–74. [PubMed] 69. Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507. [PMC free article] [PubMed] 70. Banerjee S, Reis-Filho J, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729–35. [PMC free article] [PubMed] 71. Rodriguez-Pinilla S, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12:1533–9. [PubMed] 72. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implications of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer. J Natl Cancer Inst. 2003;95:1482–5. [PubMed] 73. Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 2008;20:40–5. [PubMed] 74. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24. [PMC free article] [PubMed] 75. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81:1109–2. [PubMed]
76. Osborne CR, Kanna L, Ashfaq R, et al. Clinical and pathological characterization of basal-like breast cancer. Breast Cancer Res Treat. 2005;94 abstract 2098.
77. Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma. Cancer. 2003;98:1569–77. [PubMed] 78. Chang HR, Glaspy J, Elashoff R, Kass F, Allison MD, Chung DU. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010;116:4227–37. [PubMed] 79. Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18:94–103. [PMC free article] [PubMed] 80. Voduc KD, Cheang MC, Tyldesely S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91. [PubMed] 81. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8. [PubMed] 82. Wilkinson JB, Reed RE, Wallace MF, et al. Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011 Feb 22; [Epub ahead of print]. [PubMed] 83. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9. [PubMed] 84. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;29:1145–53. [PMC free article] [PubMed] 85. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16:53–61. [PMC free article] [PubMed] 86. Kriege M, Seynaeve C, Mijers-Haljboer H, et al. Sensitivity to first-time chemotherapy for metastatic breast cancer in BRCA 1 and BRCA 2 mutation carriers. J Clin Oncol. 2009;27:3764–71. [PubMed] 87. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol. 2010;3:42. [PMC free article] [PubMed] 88. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1427–37. [PubMed] 89. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 2009;27:526–34. [PubMed] 90. Cortez J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12:271–81. [PubMed] 91. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 2004;305:866–9. [PubMed] 92. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Res Cancer. 2010;10:194–204. [PubMed]
93. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. High beta-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correction to ixabepilone response: a retrospective analysis. J Clin Oncol. 2009;27 abstract 3587.
94. Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet. 2011;377:914–23. [PubMed]
95. Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. PResented at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX. December 16, 2008; abstract 6069.
96. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-ribose) polymerase inhibition: “Targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702–10. [PMC free article] [PubMed] 97. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. 2007;13:1383–8. [PubMed] 98. Martin-Oliva D, Aguilar-Quesada R, O’Valle F, et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006;66:5744–56. [PubMed] 99. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9(Suppl 5):10–7. [PubMed] 100. Greenberg S, Rugo HS. Triple-negative breast cancer: role for antiangiogenic agents. Cancer Journal. 2010;16:33–8. [PubMed] 101. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44:912–20. [PubMed] 102. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76. [PubMed] 103. Tan DS, Marchio C, Jones RL, et al. Triple-negative breast cancer: molecular profiling and prognostic impact in adjuvant anthrocycline-treated patients. Breast Cancer Res Treat. 2007;111:27–44. [PubMed] 104. Bian J. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis. 1996;17:1805–11. [PubMed] 105. Finn RS, Derin J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selective inhibitors growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105:319–26. [PubMed] 106. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–81. [PMC free article] [PubMed] 107. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84. [PubMed] 108. De Benedetti A, Graff JR. EIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189–99. [PubMed] 109. Jastrzebski K, Hannan KM, Tchoubrieva EB, et al. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 2007;25:209–26. [PubMed] 110. Nakamura JL, Garcia E, Pieper RO. S6 K1 plays a key role in glial transformation. Cancer Res. 2008;68:6515–23. [PMC free article] [PubMed] 111. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37. [PubMed] 112. Yang Q, Inoki K, Ikenoue T, et al. Identification of SIN1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006;20:2820–32. [PubMed] 113. Pearce LR, Huang X, Boudreau J, et al. Identification of protor as a novel Rictor-finding component of mTOR complex-2. Biochem J. 2007;405:513–22. [PubMed] 114. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation and its isoforms define three distinct mTORC2 s. Curr Biol. 2006:1865–70. [PubMed] 115. Martin J, Maseri J, Berath A, et al. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun. 2008;372:578–83. [PMC free article] [PubMed] 116. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding protein of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–302. [PubMed] 117. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. J Clin Oncol. 2009;27:4536–41. [PubMed] 118. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47. [PubMed]
119. Kline J, Chervoneva I, Freydin B, et al. Insulin-like growth factor receptor (IGF1R) is overexpressed in a subset of triple negative breast cancers. presented at American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development; 2010. Abstract A29.
120. Lerma E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) Mod Pathol. 2007;20:1200–7. [PubMed] 121. Myers MG, Grammer TC, Wang LM, et al. Insulin receptor substrate-1 mediates phosphatidylinositol 3’-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem. 1994;269:28783–9. [PubMed] 122. Heskamp S, Hannek WM, van Laarhoven, et al. ImmunoSPECT and ImmunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565–72. [PubMed] 123. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High-IGF-1R activity in triple-negative breast cancer cell lines and tumorgrafts correlate with sensitivity to anti-IGF-1R therapy. Clin Cancer Res. 2010 epub ahead of print. [PMC free article] [PubMed] 124. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62–5. [PubMed] 125. Doane AS, Damso M, Lal P, et al. An estrogen receptor negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008. [PubMed] 126. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21:488–92. [PubMed] 127. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression of estrogen receptor-positive tumors and in estrogen receptor-negative tumor with apocrine differentiation. Mod Pathol. 2010;23:205–12. [PubMed] 128. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8. [PubMed] 129. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp 90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer model. Proc Natl Acad Sci USA. 2009;106:8368–73. [PubMed] 130. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81. [PubMed] 131. Rastogi R, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85. [PubMed] 132. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34. [PubMed] 133. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Nat Cancer Ins. 2005;97:188–94. [PubMed] 134. Mehta RS. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol. 2008;26:3286–7. [PubMed] 135. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J Clin Oncol. 2005;23:5983–92. [PubMed] 136. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–71. [PMC free article] [PubMed] 137. Von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trial. Breast Cancer Res Treat. 2011;125:145–56. [PubMed] 138. Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol. 2008;19:861–70. [PubMed] 139. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stage II to III breast cancers with every-4-week-carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group study. J Clin Oncol. 2008;927:4693–700. [PubMed] 140. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 2008;62:667–72. [PubMed] 141. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005;352:2302–13. [PubMed] 142. Hugh J, Hanson J, Chon M, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168–76. [PMC free article] [PubMed] 143. Early Breast Cancer Trialists’ Collaborate Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717. [PubMed] 144. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659–68. [PubMed] 145. Rodriguez AA, Markis A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123:189–96. [PubMed] 146. Colleoni M, Cole B, Viale GV, et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010;28:2966–73. [PMC free article] [PubMed] 147. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemotherapy Pharmacol. 2008;62:667–72. [PubMed] 148. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009;201:1185–92. [PubMed]
149. Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple-negative breast cancer (TNBC): safety and efficacy. J Clin Oncol. 2009;27 abstract 551.
150. Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18:874–80. [PubMed] 151. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85. [PubMed] 152. Mamounas EP, Bryant J, Lembersky B, et al. Pacitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–96. [PubMed] 153. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010;121:261–71. [PubMed] 154. Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone plus capecitabine in anthrocycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008;8:234–41. [PubMed] 155. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7. [PubMed]
156. Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs. capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Poster presented at the San Antonio Breast Cancer Symposium; Dec 12, 2008; poster 3057.
157. Ibrahim NK. Ixabepilone development across the breast cancer continuum: a paradigm shift. Cancer Manag Res. 2010;2:169–79. [PMC free article] [PubMed] 158. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34. [PubMed] 159. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44. [PubMed]
160. Gelmon K, Hirte H, Robidoux A, et al. Can we define tumors that response to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple negative breast cancer. J Clin Oncol. 2010;28 abstract 3002.
161. Dent R, Lindeman G, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with netastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol. 2010;28:1018.
162. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:429–301. [PMC free article] [PubMed] 163. O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205–14. [PubMed] 164. Kummar S, Chen AP, Ji JJ, et al. A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. 2010;28 abstract 2605. [PMC free article] [PubMed]
165. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010;28 abstract 1019.
166. Carey LA, Sharpless NE. PARP and cancer—if it’s broke, don’t fix it. N Engl J Med. 2011;364:277–9. [PubMed] 167. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3238–47. [PubMed] 168. Robert NG, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol. 2009;27 abstract 1005. [PubMed] 169. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;205:487–94. [PubMed]
170. Carey LA, Rugo HS, Marcom PK, et al. TBCRC001: EGFR inihibition with cetuximab in metastatic triple negative (basal-like) breast cancer. J Clin Oncol. 2008;26(Suppl 15):43S. abstract 1009.
171. Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1) Ann Oncol. 2010;21(suppl8) abstract 2740.
172. O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Br Cancer Res Treat. 2007;106(Suppl 1):S32. abstract 308.
173. Nechushtan H, Steinberg H, Peretz T. Preliminary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients. J Clin Oncol. 2009;27 abstract 12018.
174. Resch G, Schaberl-Moser R, Kier P, et al. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol. 2011;22:486–7. [PubMed] 175. Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Can Res. 2004;10:346–54. [PubMed] 176. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009;115:115–21. [PubMed] 177. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005;12:S135–44. [PubMed] 178. Guix M, Granja NM, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancer. J Clin Oncol. 2008;26:897–906. [PubMed] 179. Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862–7. [PubMed] 180. Brower V. Search for new treatments intensifies for triple-negative breast cancer. J Natl Cancer Inst. 2009;101:1536–7. [PubMed] 181. Moulder S, Yan K, Huang F, et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010;9:1120–7. [PubMed] 182. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treatment with an anthracycline and taxane. J Clin Oncol. 2008;26:1810–6. [PubMed]
183. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) J Clin Oncol. 2010;28 abstract LBA1010.
184. Crown J, Dieras V, Staroslawska, et al. Phase III trial of sunitinib (SU) in combination with capecitabine © versus C in previously treated advanced breast cancer (ABC) J Clin Oncol. 2010;28 abstract LBA1011.
185. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10:7031–42. [PubMed]
186. Mayer IA, Means-Powell J, Shyr Y, Arteaga CL, et al. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. ASCO Breast Cancer Symposium; 2009. abstract 254.
187. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314–9. [PubMed] 188. Steelman LS, Mavolanic PM, Sokolosky ML, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 2008;27:4086–95. [PubMed] 189. Noh WC, Monesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Can Res. 2004;10:1013–23. [PubMed] 190. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temserolimus in advanced endocrine carcinomas. Br J Cancer. 2006;95:1148–54. [PMC free article] [PubMed]
191. Atzori F, Tabernero J, Cerbantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol. 2008;26:3519.
192. Higano CS, Yu EY, Whiting MS, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol. 2007;25 abstract 3505.
193. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol. 2008 abstract 3520.
194. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3 W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol. 2007;25 abstract 3590.
195. Carlson RH. IGF-1R biomarker points to new target in triple-negative breast cancer. Oncol Times. 2010;32:30–1.
196. Traina TA, Wolff AC, Giri D, et al. Androgen receptor inhibition for the treatment of A/ER-/PR- metastatic breast cancer. ASCO Breast Cancer Symposium; 2009. abstract 251.
197. Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the geparquinto study (GBG 44). SABCS; 2011. abstract 4–6.